What is the share price of Neuland Laboratories Ltd (NEULANDLAB) today?
The share price of NEULANDLAB as on 5th August 2026 is ₹19825. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Neuland Laboratories Ltd (NEULANDLAB) share?
The past returns of Neuland Laboratories Ltd (NEULANDLAB) share are- Past 1 week: 1.67%
- Past 1 month: 1.55%
- Past 3 months: 19.53%
- Past 6 months: 42.43%
- Past 1 year: 47.31%
- Past 3 years: 414.61%
- Past 5 years: 988.41%
What are the peers or stocks similar to Neuland Laboratories Ltd (NEULANDLAB)?
The peers or stocks similar to Neuland Laboratories Ltd (NEULANDLAB) include:What is the dividend yield % of Neuland Laboratories Ltd (NEULANDLAB) share?
The current dividend yield of Neuland Laboratories Ltd (NEULANDLAB) is 0.18.What is the market cap of Neuland Laboratories Ltd (NEULANDLAB) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Neuland Laboratories Ltd (NEULANDLAB) is ₹24727.05 Cr as of 5th August 2026.What is the 52 week high and low of Neuland Laboratories Ltd (NEULANDLAB) share?
The 52-week high of Neuland Laboratories Ltd (NEULANDLAB) is ₹20089 and the 52-week low is ₹11500.What is the PE and PB ratio of Neuland Laboratories Ltd (NEULANDLAB) stock?
The P/E (price-to-earnings) ratio of Neuland Laboratories Ltd (NEULANDLAB) is 67.93. The P/B (price-to-book) ratio is 13.19.Which sector does Neuland Laboratories Ltd (NEULANDLAB) belong to?
Neuland Laboratories Ltd (NEULANDLAB) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Neuland Laboratories Ltd (NEULANDLAB) shares?
You can directly buy Neuland Laboratories Ltd (NEULANDLAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Neuland Laboratories Ltd
NEULANDLAB Share Price
NSE₹19,825.002.86% (+552.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
NEULANDLAB Stock Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
NEULANDLAB Performance & Key Metrics
NEULANDLAB Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 67.93 | 13.19 | 0.18% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 45.96 | 6.02 | 0.51% |
100%
Analysts have suggested that investors can buy this stock
from 4 analysts
Price Upside
Earnings Growth
Rev. Growth
NEULANDLAB Company Profile
Neuland Laboratories Limited is engaged in manufacturing active pharmaceutical ingredient (API). The Company also provides custom manufacturing solutions (CMS) to develop and manufacture pharmaceutical ingredients and intermediates.
SUNPHARMA
PE Ratio
41.05
41.05
1Y Return
19.64%
19.64%
Buy Reco %
93.55
93.55
TORNTPHARM
PE Ratio
88.44
88.44
1Y Return
39.23%
39.23%
Buy Reco %
82.14
82.14
CIPLA
PE Ratio
30.40
30.40
1Y Return
3.64%
3.64%
Buy Reco %
63.89
63.89
ZYDUSLIFE
PE Ratio
22.36
22.36
1Y Return
17.85%
17.85%
Buy Reco %
55.17
55.17
LUPIN
PE Ratio
20.66
20.66
1Y Return
28.04%
28.04%
Buy Reco %
55.56
55.56
NEULANDLAB Sentiment Analysis
NEULANDLAB Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
NEULANDLAB Stock Summary · May 2026
Management framed FY26 as a recovery year with meaningful top‑line and margin improvement, while stressing that quarter‑to‑quarter lumpiness and growing capital requirements will shape near‑term execution. FY26 revenue was INR 2,053.1 crore, and free cash flow was negative INR 49.4 crore as higher working capital and capital spending absorbed cash. Management emphasized scaling CDMO commercializations, accelerating peptide manufacturing and R&D capacity (a new peptide facility is on track for July) and prioritizing business development around clinical and near‑commercial molecules, alongside strengthened key‑account support. They acknowledged revenue volatility from shipment timing, currency moves and late‑quarter freight pressure, and noted margins had benefited from mix and FX tailwinds. To protect margins and returns they flagged tighter working‑capital discipline, cost and process improvements, and phased, milestone‑tied capex as three sites approach high utilization. Near term, management expects lumpy growth over the next 2–3 years, a clearer upward trend over 10–12 quarters, normalization of working capital in FY27 and roughly one commercialization in FY27.
NEULANDLAB Stock Growth Drivers
NEULANDLAB Stock Growth Drivers
6Outstanding FY26 financial performance and margin expansion
Neuland delivered markedly stronger financial results in FY26 and Q4, with Q4 total income of
Robust balance sheet and disciplined capital allocation
The company exits Q4FY26 in a net cash position with net debt of negative INR
NEULANDLAB Stock Challenges
NEULANDLAB Stock Challenges
8Cash flow strain and worsening liquidity metrics
Free cash flow turned negative at INR 49.4 crore for FY26, driven primarily by higher
Revenue volatility and underwhelming multi‑year growth momentum
The business exhibits pronounced quarter‑to‑quarter lumpiness with record Q4s and muted intervening quarters, producing timing‑driven
NEULANDLAB Forecast
NEULANDLAB Forecasts
Price
Revenue
Earnings
NEULANDLAB Share Price Forecast
NEULANDLAB Share Price Forecast
2026
Current
₹19,273.00
Baseline
Forecast for Aug 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹19,273.00
Baseline
Forecast for Aug 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
NEULANDLAB Company Revenue Forecast
NEULANDLAB Company Revenue Forecast
2026
Current
₹2.05
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2026
Current
₹2.05
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
NEULANDLAB Stock EPS (Earnings Per Share) Forecast
NEULANDLAB Stock EPS (Earnings Per Share) Forecast
2026
Current
₹283.71
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹283.71
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
NEULANDLAB
NEULANDLAB
Income
Balance Sheet
Cash Flow
Quarterly Normal View
NEULANDLAB Income Statement
NEULANDLAB Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 394.93 | 390.37 | 465.03 | 315.18 | 457.72 | 335.82 | 300.61 | 516.07 | 447.76 | 788.71 | ||||||||||
Operating & Other expenses | 271.56 | 278.09 | 316.24 | 248.62 | 311.43 | 277.29 | 258.26 | 358.73 | 362.58 | 468.92 | ||||||||||
EBITDA | 123.37 | 112.28 | 148.79 | 66.56 | 146.29 | 58.53 | 42.35 | 157.34 | 85.18 | 319.79 | ||||||||||
| Depreciation/Amortization | 15.14 | 16.46 | 16.28 | 16.07 | 16.30 | 16.89 | 20.19 | 22.54 | 23.92 | 25.09 | ||||||||||
| PBIT | 108.23 | 95.82 | 132.51 | 50.49 | 129.99 | 41.64 | 22.16 | 134.80 | 61.26 | 294.70 | ||||||||||
| Interest & Other Items | 3.74 | 3.61 | 2.67 | 1.06 | 2.22 | 2.35 | 4.58 | 5.37 | 6.79 | 7.21 | ||||||||||
| PBT | 104.49 | 92.21 | 129.84 | 49.43 | 127.77 | 39.29 | 17.58 | 129.43 | 54.47 | 287.49 | ||||||||||
| Taxes & Other Items | 23.09 | 24.64 | 31.97 | 16.58 | 26.18 | 11.49 | 3.67 | 32.58 | 13.90 | 74.82 | ||||||||||
| Net Income | 81.40 | 67.57 | 97.87 | 32.85 | 101.59 | 27.80 | 13.91 | 96.85 | 40.57 | 212.67 | ||||||||||
| EPS | 63.44 | 52.66 | 76.28 | 25.60 | 79.18 | 21.67 | 10.83 | 75.49 | 31.62 | 165.76 |
NEULANDLAB Company Updates
NEULANDLAB Stock Peers
NEULANDLAB Past Performance & Peer Comparison
NEULANDLAB Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Neuland Laboratories Ltd | 67.93 | 13.19 | 0.18% |
| Sun Pharmaceutical Industries Ltd | 41.05 | 5.62 | 0.81% |
| Torrent Pharmaceuticals Ltd | 88.44 | 10.88 | 0.67% |
| Cipla Ltd | 30.40 | 3.42 | 0.89% |
NEULANDLAB Stock Price Comparison
Compare NEULANDLAB with any stock or ETFCompare NEULANDLAB with any stock or ETF
NEULANDLAB
NEULANDLAB Holdings
NEULANDLAB Shareholdings
NEULANDLAB Promoter Holdings Trend
NEULANDLAB Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
NEULANDLAB Institutional Holdings Trend
NEULANDLAB Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
NEULANDLAB Shareholding Pattern
NEULANDLAB Shareholding Pattern
NEULANDLAB Shareholding History
NEULANDLAB Shareholding History
Foreign Institutions
Mutual Funds Invested in NEULANDLAB
Mutual Funds Invested in NEULANDLAB
No mutual funds holding trends are available
Top 5 Mutual Funds holding Neuland Laboratories Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.6966% | Percentage of the fund’s portfolio invested in the stock 1.86% | Change in the portfolio weight of the stock over the last 3 months 0.11% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 51/93 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.2137% | Percentage of the fund’s portfolio invested in the stock 1.68% | Change in the portfolio weight of the stock over the last 3 months 0.28% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 65/118 (+2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.9100% | Percentage of the fund’s portfolio invested in the stock 3.25% | Change in the portfolio weight of the stock over the last 3 months 1.68% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 48/94 (+7) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing NEULANDLAB stock
smallcases containing NEULANDLAB stock
Looks like this stock is not in any smallcase yet.
NEULANDLAB Events
NEULANDLAB Events
NEULANDLAB Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
NEULANDLAB has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.18%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.76 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
NEULANDLAB Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
NEULANDLAB has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.18%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.76 every year
NEULANDLAB Upcoming Dividends
NEULANDLAB Upcoming Dividends
No upcoming dividends are available
NEULANDLAB Past Dividends
NEULANDLAB Past Dividends
Cash Dividend
Ex DateEx DateJul 24, 2026
Final
Final | Div/Share: ₹34.00
Dividend/Share
₹34.00
Ex DateEx Date
Jul 24, 2026
Cash Dividend
Ex DateEx DateJul 18, 2025
Final
Final | Div/Share: ₹12.00
Dividend/Share
₹12.00
Ex DateEx Date
Jul 18, 2025
Cash Dividend
Ex DateEx DateJul 12, 2024
Final
Final | Div/Share: ₹14.00
Dividend/Share
₹14.00
Ex DateEx Date
Jul 12, 2024
Cash Dividend
Ex DateEx DateJul 11, 2023
Final
Final | Div/Share: ₹10.00
Dividend/Share
₹10.00
Ex DateEx Date
Jul 11, 2023
Cash Dividend
Ex DateEx DateJul 14, 2022
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Jul 14, 2022
NEULANDLAB Stock News & Opinions
NEULANDLAB Stock News & Opinions
Articles & Videos
Corporate
Corporate
Neuland Laboratories to announce Quarterly ResultNeuland Laboratories will hold a meeting of the Board of Directors of the Company on 5 August 2026.
2 weeks agoCapital Market - Live
Corporate
Corporate
Neuland Laboratories receives affirmation in credit ratingsNeuland Laboratories has received affirmation in credit ratings for bank facilities at IND A+/ Positive / IND A1.
3 weeks agoCapital Market - Live
Corporate
Corporate
Neuland Laboratories board approves capacity additional at Unit 1The board of Neuland Laboratories at its meeting held on 12 May 2026 has approved the enhancement of capacity at its Unit 1 located at Bonthapally Village, Gummadidala Mandal, Sangareddy District, Telangana. Existing capacity - 256 KL Existing capacity utilization - 91% Proposed capacity addition - 120.5 KL Period for capacity addition - within 12-18 months Investment required - Rs 143.4 crore (funded through internal accruals and borrowings)
2 months agoCapital Market - Live
Corporate
Corporate
Neuland Laboratories board appoints directorThe board of Neuland Laboratories at its meeting held on 12 May 2026 has approved the appointment of Dr. Mauricio Futran (DIN: 11699767) as an Additional Director of the Company, categorized as Non-Executive Non-Independent, w.e.f. 12 May 2026.
2 months agoCapital Market - Live
Corporate
Corporate
Neuland Laboratories fixes record date for final dividendNeuland Laboratories has fixed 24 July 2026 as record date for purpose of determining the shareholders eligible to receive final dividend of Rs 34 per equity share of Re 10 for FY 2026.
2 months agoCapital Market - Live
Earnings
Earnings
Neuland Laboratories consolidated net profit rises 664.72% in the March 2026 quarterNet profit of Neuland Laboratories rose 664.72% to Rs 212.67 crore in the quarter ended March 2026 as against Rs 27.81 crore during the previous quarter ended March 2025. Sales rose 136.40% to Rs 776.25 crore in the quarter ended March 2026 as against Rs 328.36 crore during the previous quarter ended March 2025. For the full year,net profit rose 39.94% to Rs 364.00 crore in the year ended March 2026 as against Rs 260.11 crore during the previous year ended March 2025. Sales rose 36.98% to Rs 2022.99 crore in the year ended March 2026 as against Rs 1476.84 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales776.25328.36 136 2022.991476.84 37 OPM %39.5915.56 -28.4021.89 - PBDT312.5856.19 456 580.72335.48 73 PBT287.4939.30 632 488.98269.93 81 NP212.6727.81 665 364.00260.11 40 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Corporate
Neuland Laboratories to convene AGMNeuland Laboratories announced that the 42th Annual General Meeting(AGM) of the company will be held on 4 August 2026.
2 months agoCapital Market - Live
Corporate
Corporate
Board of Neuland Laboratories recommends final dividendNeuland Laboratories announced that the Board of Directors of the Company at its meeting held on 12 May 2026, inter alia, have recommended the final dividend of Rs 34 per equity Share (i.e. 340%) , subject to the approval of the shareholders.
2 months agoCapital Market - Live
Corporate
Corporate
Neuland Laboratories to conduct board meetingNeuland Laboratories will hold a meeting of the Board of Directors of the Company on 12 May 2026.
3 months agoCapital Market - Live
Earnings
Earnings
Neuland Laboratories consolidated net profit declines 60.06% in the December 2025 quarterNet profit of Neuland Laboratories declined 60.06% to Rs 40.57 crore in the quarter ended December 2025 as against Rs 101.59 crore during the previous quarter ended December 2024. Sales rose 10.47% to Rs 439.71 crore in the quarter ended December 2025 as against Rs 398.03 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales439.71398.03 10 OPM %17.5421.76 - PBDT78.4088.29 -11 PBT54.4871.98 -24 NP40.57101.59 -60 Powered by Capital Market - Live
5 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 16.59%, vs industry avg of 12.48%
Over the last 5 years, market share increased from 0.34% to 0.4%
Over the last 5 years, net income has grown at a yearly rate of 35.18%, vs industry avg of 10.55%